This great university has been preeminent in biomedical science, and the establishment of a Comprehensive Cancer Center will, I am sure, enhance Yale's contribution both to the fundamental understanding of cancer and to the quality of clinical care for the cancer patient.
science. These are the most frequently voiced complaints. There are others, but the ones I have mentioned provide more than a full plate for this morning's allocation of time.
First, is the cancer program supporting enough basic research? To put the answer to that question in context, let us take a brief look at a bit of history. In 1970, when the Senate of the United States appointed a Senate panel to make recommendations with respect to cancer research, biomedical research in general and cancer research in particular were on the back burner. The budget of the NCI was $180 million. In 1971, as a result of the discussions which the Senate panel stimulated in the Congress, the NCI budget was increased to $228 million. In 1972, the first year after the passage of the National Cancer Act, the budget was $378 million. In 1973 it was $432 million. In 1974, $589 million. In 1975, $691 million. In 1976, $762 million, and this year's budget looks like $815 million. As a result of these increases, we have been able to give this country programs in both basic biomedical research and clinically-oriented research in cancer that are unprecedented, both in their scope and their excellence. While the other institutes of the NIH have not had increases comparable to cancer, the total NIH budget for biomedical research is two and one half billion dollars in 1977 compared to 1 billion, 143 million dollars in 1970.
In 1976, 52% of the NCI budget, or $396 million, was spent on basic research. This compares with less than $100 million in 1970. Throughout the past five years, the National Cancer Program has consistently devoted about one-half of the substantial budget increases to the support of basic research. Moreover, a large portion of that is investigator-initiated, peer-reviewed, grant-supported, basic research. For example, of the $396 million devoted to basic research in this year, $152 million represents traditional research grants, $58 million represents the basic research portion of program project grants, $30 million represents support of basic research in the excellent Intramural Program on the NIH campus, $30 million is for construction and fellowship grants in support of basic research, and $79 million represents research contracts in areas, such as virology, which were already being supported by the contract mechanism prior to the passage of the National Cancer Act of 1971, and which, with strengthened peer review, we have continued to support by contract rather than disrupt good ongoing programs. These amounts are spent in support of fundamental research to expand our knowledge at the most basic levels. So when my friend, Arthur Kornberg, says, "We don't know enough about biology to do a proper job in spending huge amounts of money successfully on cancer," it seems to me that this loses sight of the fact that a very substantial amount of the money provided for cancer research goes to the support of excellent basic biological research in the very areas of ignorance to which Dr. Kornberg refers.
During a recent hearing of the Senate Health Subcommittee, I was asked whether we should be supporting so much basic research under the cancer program. The question was, "Can we afford so much basic research or should we devote our funds to activities where the probable payoff is more immediate and more apparent?" My answer is that we cannot afford not to support basic research. Without it, there will be no payoffs. Basic research is still the lifeline of medicine. It is essential in order to provide the science base upon which to build improved technologies for One thing that worries me is the developing notion that there is good basic biomedical research that is relevant and there is good basic biomedical research that is not relevant, and that scientists or administrators should be able to tell the difference in advance. I doubt that relevance in basic biomedical science is identifiable in advance. The individual questions are much too small. It is the total of the science base that becomes relevant, and any building block that elucidates cell structure or mechanisms is relevant, although it may not seem so when described separately in advance. We must not allow this notion or any other to erode our support of the best basic science.
Simultaneously with the expansion of our knowledge through the support of fundamental research, we must also make the best effort of which we are capable today in the areas of prevention, diagnosis and treatment of cancer. This means the support of applied research where an adequate science base exists and the support of clinical research for the development, application, and trial of the best technologies of which we are capable. In 1976, $241 million was obligated under the cancer program for treatment research, of which $68.5 million was spent for the direct support of research in clinical treatment. While we have not had spectacular breakthroughs in cancer comparable to the antibiotics in infectious diseases or the polio vaccine there is no question that the cancer patient has a better chance today in the hands of good cancer doctors than has been true at any time in the past. Not only are we doing better all the time with acute lymphocytic leukemia, osteogenic sarcoma, and a number of other tumors in children, Hodgkin's disease and other lymphomas, but a new era has begun in the use of combination therapy in treating the more common tumors. Postoperative or postradiation chemotherapy appears to be effective in a large number of cases to avoid metastasis and recurrence where surgery or radiation or both are used to eliminate the primary tumor. In addition, it has now become apparent that tumors are antigenic and immunotherapy therefore will almost certainly become an important tool in treatment, particularly in the postoperative periods when low volumes of tumor exist.
It is quite possible then that even with our existing tools we may be able to improve significantly the survival of patients today. In those cases where tumors are resectable, there has been a tremendous increase in the past three or four years in the emphasis upon the use of chemotherapy and immunotherapy postoperatively to treat those patients with detectable or nondetectable micrometastases. Early results with these techniques are very encouraging and it now appears likely that cure rates will be materially increased for such common cancers as breast and colon cancer over those achieved in the past by surgery alone.
These recent developments represent a drastic alteration in the way medicine is practiced in this country. Utilization of these advances in cancer treatment often requires the melding of the talents of several specialties, the surgeon or radiation therapist, the medical or pediatric oncologist, and the researcher, and such a joint effort has not been and is not today common medical practice. It must become more common in cancer therapy, so long as our basic knowledge is at present levels, and this is an area where I hope we can look to the Comprehensive Cancer Centers such as the one here at Yale to lead the way.
Under the Cancer Control Program we are mandated by the Congress to extend our clinical research to demonstration programs in those areas where beneficial technologies exist but where their acceptance and utilization is not widespread. This is an area that troubles a great many scientists because they are concerned that the entry of the NCI into the service area, even to this extent, will ultimately result in the diminishing of its resources for research. Fortunately, the Congress has to date been willing to budget the control activities separately, and I see no indication of a change in this policy. So long as this is true, the NCI should be able to expend the control dollars usefully without diminishing its research capability.
As for targeting, I wish that I could make clear once and for all the fact that those who manage the national cancer effort are not obsessed with the idea of targeting. There is some applied research that can and should be targeted because the science base exists, and in those cases, with the advice of the best scientists available, a targeted effort is made. However, we are as aware as anyone anywhere of the limitations of targeted research, and we are not attempting to target the basic research that will give us the understanding of the origins and nature of cancer. Similarly, with respect to the issue of contracts vs. grants, we have been substantially diminishing the percentage of contract support and increasing grant support in the area of basic science, and we intend to continue to do so. One of the problems of communications has been that our budgets often lump all contracts together, and this figure is sometimes taken by members of the scientific community to represent contract research. In fact, over half of the contract expenditures are for necessary supplies and services which can only be obtained through the contract mechanism. The contract mechanism is used for the support of basic research today primarily in those areas where it was in use prior to the passage of the National Cancer Act, and in these limited areas its use with strengthened peer-review has been continued in order not to impede strong ongoing programs. However, the present management of the NCI has been de-emphasizing the contract mechanism in the support of basic research and will continue to do so.
This brings me to the National Cancer Plan which has been the subject of so much criticism from so many scientists. When Dr. James Watson was reported last year as having said at M.I.T. that the National Cancer Program was a "sham," he was, in fact, talking about the National Cancer Plan. He made this somewhat clearer in a letter of apology than he did in his speech, but there is no question that There is a legitimate worry about the Comprehensive Cancer Centers which relates to future funding in the event of the recognition of too many such centers. Comprehensive Cancer Centers must compete on the merits with all other institutions for the cancer research dollar. Therefore, if too many centers are recognized and we have centers which cannot compete on the merits, we will then be in a position of having recognized centers which we are unable to support. The fear is that, under those circumstances, political pressures would be brought to bear which would force the support of the comprehensive centers at the expense of other institutions capable of better cancer research. The answer to this perceived future problem is strictly to limit the recognition of the comprehensive centers and to recognize them only at institutions that are established academic and scientific leaders clearly capable of competing on the merits.
The most serious mistake we have made in the support of our biomedical research during the short period that I have been actively associated with this enterprise was the discontinuance byOMB of the biomedical fellowship and training programs. It is absolutely essential to our success in the cancer program and in biomedical research generally that we bring a portion of our brightest young people into these programs, and fellowships and training grants have proved to be the most effective and most economical ways of doing that. These are among the best dollars we spend in terms of value received.
Fortunately, one way or another the NCI has been able to keep its training programs going at about the same dollar level as existed before theOMB action. However, the training programs of other parts of the NIH, particularly the predoctoral programs of GMS, have been adversely affected, and that ultimately affects the cancer program as surely as if these programs were in the NCI.
One of the worst aspects of the training picture during the past few years under both the Weinberger Program and the National Research Training Act has been the on again-off again uncertainty that comes with defining new programs, producing new regulations, not having funds in certain periods, having funds in other periods, and putting the whole research establishment in the hurry-up-and-wait, now-you-have-it-now-you-don't posture. However, we are supporting training substantially, and I hope we can get a uniform understanding and a uniform program that can go on year after year without the turbulence that has characterized the past several years. This has been very distressing, I know, from the standpoint of the institutions, and it has made for less efficient expenditure of the federal dollars in this field.
Before concluding, I would like to say a few words about the biomedical research budget, because there is no question that the combined problems of inflation and recession and the economic difficulties which confront us have created great pressure for the reduction of federal expenditures on biomedical research. This is one of the few areas that can be reduced and therefore it is a prime target. However, it is my opinion, and has been my advice to the President and to the Congress that it would be a serious mistake to cut these programs in such a way as to lose the momentum that has been established. I think we must continue our federal support.
Unfortunately, in a free enterprise system, basic biomedical research cannot be carried forward on the scale that is required without federal support. Profit incentives are not there to support adequate basic research in this area, and philanthropic institutions, while providing the bulk of the facilities and personnel needed for this enterprise, must have government help in order to stimulate their activities and to sustain them at the level which the public interest requires. It is this mix of public support and private sector initiative that has made our biomedical research establishment the envy of the world.
The cost of medical care is such an enormous and increasing expense for our people and, therefore, for the government, that we cannot afford to starve the research efforts which will provide us the knowledge we need to avoid the crushing burdens of medical care. If it were not for the results of past biomedical research, we would still be saddled today with the horrendous costs and burdens of tuberculosis, polio, and all of the infectious diseases which through the products of research have been virtually eliminated from our medical picture. We must continue our research until cancer, heart disease, stroke, arthritis, multiple sclerosis, diabetes, and other diseases that agonize our people and fill our hospitals have been added, or largely added, to that list.
If any well-run business were spending $130 billion per year on medical care, it would be spending at least 5% of that amount on research to reduce those costs. While we cannot go to that level under today's circumstances, sound business judgment requires that we not cut back on the present effort.
Finally, the federal expenditures in biomedical research are leverage dollars. Hundreds of millions of dollars of institutional facilities built by our universities and other philanthropic institutions, and thousands of people whose salaries are paid by these institutions, are mobilized in the cause of biomedical research by the relatively few federal dollars that are spent in stimulating this activity. However, stop the flow of federal dollars under today's circumstances, and these essential activities will grind virtually to a standstill. This we must not do.
In conclusion, all of you in the scientific and medical community, and all of us connected with the program must continue to explain at every opportunity to the American people and to the Congress that the cancer program is a vast undertaking which will require long-term support and great patience. We are still far away from being able to put either a date or a price tag on the ultimate conquest of cancer. We are making progress in our understanding of this disease, and there is no question that the benefits of our research are increasingly available to the American people in the form of better treatment as time goes by. But it is a long road that will require patience and constancy on the part of the Congress, the administration, and the public. In fact, at this stage of our progress, it is true in a very real sense that "the goal is the course we travel together, and the end is only the beginning."
And 
